Orasis CEO, Elad Kedar, Interviewed by Endpoints News about Recent Series C Round
Elad Kedar discuss the Presbyopia Market and the closing of the recent Series C round with Endpoints News.
Orasis Closes $30MM Series C Round for Phase III Trials and Pre-Commercialization Activities.
Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on developing an innovative pharmaceutical solution for the treatment of presbyopia symptoms, today announced the closing of a $30 million Series C financing. The financing was co-led by new investor Bluestem Capital and returning investor Visionary Ventures, with participation from other returning investors Sequoia Capital, SBI (Japan) Innovation Fund, Maverick Ventures, LifeSci Venture Partners and additional investors.